Long-term Observational Study to Evaluation the Safety of FURESTEM-RA Inj

Observational Study to Evaluate the Safety of FURESTEM-RA Inj. in Moderate to Severe Rheumatoid Arthritis Patients Who Participated in Phase 1 Clinical Trial of FURESTEM-RA Inj

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03106259

Enrollment

Registered

2017-04-10

Start date

2016-06-29

Completion date

2021-03-21

Last updated

2018-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Keywords

FURESTEM-RA

Brief summary

Observational Study to evaluate the safety of FURESTEM-RA lnj. in moderate to severe rheumatoid arthritis patients who participated in phase 1 clinical trial of FURESTEM-RA lnj.

Detailed description

This is a observational study, single center, open label, study of safety of FURESTEM-RA Inj. in subjects with moderate to severe rheumatoid arthritis. Subjects participating in this observational study originally participated in study FURESTEM-RA Inj. \[NCT02221258\]

Interventions

DRUGFURESTEM-RA Inj.

Non-interventional observational study

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

19 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Subjects participating in this observational study originally participated in study FURESTEM-RA Inj.\[NCT02221258\] * Subject who understands and voluntarily sign an informed consent form

Exclusion criteria

* In case follow-up is not possible from end of clinical trial Phase 1 to end of this study period

Design outcomes

Primary

Measure	Time frame	Description
Safety of FURESTEM-RA Inj.	5 years	Evaluate the number of adverse events Safety of FURESTEM-RA Inj.

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026